ViatrisHAM:VIA +1.71%58 PB Ratio is 1.31 as of Jun. 26, 2026, which is 66% above its 10-year median of 0.79. GuruFocus rates HAM:VIA with a GF Score™ of 58/100 and a GF Value™ of €9.77 (Significantly Overvalued). The stock has 7 warning signs investors should review. Among 922 Drug Manufacturers companies, Viatris ranks better than 65.18% on this metric.
The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. As of today (2026-06-26), Viatris's share price is €14.264. Viatris's Book Value per Share for the quarter that ended in Mar. 2026 was €10.89. Hence, Viatris's PB Ratio of today is 1.31.
Warning Sign:
Viatris Inc stock PB Ratio (=1.28) is close to 5-year high of 1.36.
The historical rank and industry rank for Viatris's PB Ratio or its related term are showing as below:
HAM:VIA'
s PB Ratio Range Over the Past 10 Years
Min: 0.5 Med: 0.79 Max: 2.39
Current: 1.28
During the past 13 years, Viatris's highest PB Ratio was 2.39. The lowest was 0.50. And the median was 0.79.
HAM:VIA's PB Ratio is ranked better than 65.18% of 922
companies
in the Drug Manufacturers industry
Industry Median: 1.825
vs HAM:VIA: 1.28
During the past 12 months, Viatris's average Book Value Per Share Growth Rate was -4.60% per year.
During the past 3 years, the average Book Value Per Share Growth Rate was -9.70% per year.
During the past 5 years, the average Book Value Per Share Growth Rate was -6.20% per year.
During the past 10 years, the average Book Value Per Share Growth Rate was -4.90% per year.
During the past 13 years, the highest 3-Year average Book Value Per Share Growth Rate of Viatris was 44.80% per year. The lowest was -13.10% per year. And the median was 11.30% per year.
The PB Ratio works the best for the businesses that earn most of their profit from their assets, e.g. banks and insurance companies.
Be Aware
Some businesses have very light assets, such as software companies or insurance agencies. The PB Ratio does not work well for these companies. Some companies even have negative equity, so the PB Ratio cannot be applied to them.
Viatris PB Ratio Related Terms
Viatris PB Ratio Historical Data
* Premium members only.
The historical data trend for Viatris's PB Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Viatris's PB Ratio, along with its competitors' market caps and PB Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Viatris PB Ratio vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Viatris's PB Ratio distribution charts can be found below:
* The bar in red indicates where Viatris's PB Ratio falls into.
The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. It is a ratio widely used to value stocks.
Viatris's PB Ratio for today is calculated as follows:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
A closely related ratio is called Price-to-Tangible-Book. The difference between Price-to-Tangible-Book and PB Ratio is that book value other than intangibles are used in the calculation.
Viatris (HAM:VIA) has a PB Ratio of 1.31 as of Jun. 26, 2026. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on Viatris and its competitors. This is 66% above median its historical median of 0.79. Over the past decade, Viatris' PB Ratio has ranged from 0.50 to 2.39. According to the industry distribution chart, Viatris ranks #321 out of 922 companies in the Drug Manufacturers industry, placing it in the top 34.8%.
Is Viatris' PB Ratio too high?
Viatris' current PB Ratio of 1.31 is 66% above median its 10-year median of 0.79. Over the past 10 years, this metric has ranged from a low of 0.50 to a high of 2.39. The Drug Manufacturers industry median PB Ratio is 1.83. Viatris' value of 1.31 is 28.2% below this industry median. Based on the distribution chart, Viatris ranks #321 out of 922 companies in the Drug Manufacturers industry, which is above the industry midpoint. Overall, Viatris has a GF Score™ of 58/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Viatris' PB Ratio compare to NBIX and UTHR?
According to the Drug Manufacturers industry distribution chart, Viatris ranks #321 out of 922 companies for PB Ratio. This puts Viatris in the upper half of its industry. The industry median PB Ratio is 1.83. Viatris' value of 1.31 is 28.2% below this benchmark. Historically, Viatris' own PB Ratio has ranged from 0.50 to 2.39 over the past decade. While the company's 10-year median is 0.79 vs. the industry median of 1.83, Viatris has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PB Ratio for a Drug Manufacturers company?
The median PB Ratio among Drug Manufacturers companies is 1.83, based on 922 companies in the industry. Companies in the top quartile (top 25%) have a PB Ratio significantly above this median, while those in the bottom quartile fall well below. However, PB Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Viatris's current PB Ratio of 1.31 is 28.2% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PB Ratio mean?
A high PB Ratio can signal that a stock is expensive relative to its fundamentals. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on Viatris and its competitors. For the Drug Manufacturers industry, the median PB Ratio is 1.83 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Viatris's current PB Ratio is 1.31, which is 66% above median its own 10-year median of 0.79. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Viatris stock overvalued right now?
Based on GuruFocus' analysis, Viatris (HAM:VIA) is currently considered Significantly Overvalued. The stock's GF Value™ is €9.77, compared to a current price of €14.26 — trading 46% above its estimated fair value. The current PB Ratio is 1.31, which is 66% above median its 10-year median of 0.79 and 28.2% below the Drug Manufacturers industry median of 1.83. Viatris' overall GF Score™ is 58/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PB Ratio calculated?
PB Ratio is calculated from a company's financial statements. For Viatris (HAM:VIA), the current PB Ratio is 1.31 as of Jun. 26, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Viatris (HAM:VIA) Overvalued in 2026?
Based on GuruFocus' analysis, Viatris stock appears to be overvalued.
The current stock price of €14.26 is trading 46% above its estimated GF Value™ of €9.77.
GuruFocus considers Viatris to be Significantly Overvalued.
Key valuation signals for HAM:VIA:
PB Ratio: 1.31 (66% above median its 10-year median of 0.79)
GF Value™: €9.77 vs. price of €14.26 (46% above fair value)
Industry Position: 28.2% below the Drug Manufacturers median (#321 of 922)
No single metric tells the full story. See the HAM:VIA stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Viatris was formed in November 2020 through the combination of Upjohn, a wholly owned subsidiary of Pfizer that specialized in off-patent drugs, and Mylan, a global pharmaceutical manufacturer that focused on generic and specialty drugs. By joining forces, Viatris became one of the largest generic drug manufacturers in the world, servicing over 165 countries. Generics (commoditized and complex) and biosimilars make up roughly 40% of Viatris' total sales. The remaining 60% of sales are derived from its portfolio of legacy products, which includes Lipitor, Norvasc, Lyrica, and Viagra. While it covers more than 10 major therapeutic areas, Viatris has identified dermatology, ophthalmology, and gastroenterology as its three key areas of focus for future innovations.
58GF Score
Get the complete analysis for HAM:VIA
PB Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
HAM:VIA has been successfully added to your 
